| | Class 1 Device Recall Dialysate Concentrate |  |
| Date Initiated by Firm | April 11, 2025 |
| Date Posted | May 14, 2025 |
| Recall Status1 |
Open3, Classified |
| Recall Number | Z-1730-2025 |
| Recall Event ID |
96646 |
| 510(K)Number | K012547 |
| Product Classification |
Dialysate concentrate for hemodialysis (liquid or powder) - Product Code KPO
|
| Product | MedicaLyte Liquid Bicarbonate Concentrate. Model Numbers: BC+201 (45X), BC+100 36.83X.
Plastic bottle packaged in corrugated shipper cases (4 bottles per shipper case). |
| Code Information |
a. Model Number: BC+201 (45X). Case UDI-DI: 10817411022821, Bottle UDI-DI: 00817411022824. All lot numbers.
b. Model Number: BC+100 36.83X. Case UDI-DI: 10817411022814, Bottle UDI-DI 00817411022817. Lot Numbers: N3C014, N3C018, N3F018, N4C010, N4C012, N4E004, N4L021, N4L022, N4L037, N5A044.
|
| FEI Number |
1000142899
|
Recalling Firm/ Manufacturer |
Nipro Renal Soultions USA, Corporation 509 Fishing Creek Rd Lewisberry PA 17339-9517
|
| For Additional Information Contact | Jessica Oswald-McLeod 305-432-6699 |
Manufacturer Reason for Recall | Potential for the presence of visible foreign matter. |
FDA Determined Cause 2 | Process control |
| Action | Nipro Renal notified consignees on about 04/11/2025 via "URGENT: MEDICAL DEVICE RECALL" letter dated 4/10/2025. Consignees were instructed to identify and isolate any inventory from the affected BC+201 lots, cease use of those affected lots, complete and return the Business Reply Card even if you do not have the recalled product to Nipro4621@sedgwick.com or via fax to 877-496-5036 and arrange the return of any affected lots on hand via phone 1-877-546-0126. Additionally, consignees were instructed to notify any accounts if lots were further distributed.
If you have any questions, call 305- 432-6699 or email: jessicao@nipromed.com.
Nipro expanded the recall and notified specific international consignees on about 05/30/2025 concerning affected BC+100 lots. Customers were provided the same instructions to return all affected units and notify customers if further distributed
On 06/02/2025, Nipro Renal expanded the recall again to include all BC+201 lot numbers and notified consignees via letter. The letter notified consignees that all lots were affected and instructed them to cease distribution, quarantine any on hand, complete and return the response form, and arrange for return of any lots on hand. Additionally, customers were instructed to forward the notification to customers if further distributed.
|
| Quantity in Commerce | 816,840 units (BC+201), 39,228 units (BC+100) |
| Distribution | US Nationwide distribution in the states of AZ, CA, CO, DE, FL, GA, IL, KS, LA, MA, MI, MN, MO, NC, NJ, NV, NY, OH, OK, OR, PA, SC, TX, UT, VA, WA, PR. International distribution to Guatemala and Panama. |
| Total Product Life Cycle | TPLC Device Report |
|
1 A record in this database is created when a firm initiates a correction or removal action. The record is updated if the FDA identifies a violation and classifies the action as a recall, and it is updated for a final time when the recall is terminated. Learn more about medical device recalls. 2 Per FDA policy, recall cause determinations are subject to modification up to the point of termination of the recall. 3 The manufacturer has initiated the recall and not all products have been corrected or removed. This record will be updated as the status changes.
|
| 510(K) Database | 510(K)s with Product Code = KPO
|
|
|
|